What Happened?
Cambridge, MA-based Fulcrum Therapeutics Appointed Robert Gould as Chief Executive Officer
About the Company
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
About the Person
Robert Gould is Chief Executive Officer at Fulcrum Therapeutics. Previously, Robert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile